Gritstone bio, Inc. Common Stock
GRTS
GRTS: Gritstone Bio Inc is a biotechnology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types and infectious diseases. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors, which includes GRANITE, SLATE, BiSAb, among others.
moreShow GRTS Financials
Recent trades of GRTS by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by GRTS's directors and management
Government lobbying spending instances
-
$10,000 Apr 20, 2021 Issue: Pharmacy
-
$30,000 Aug 03, 2020 Issue: Pharmacy
New patents grants
-
Patent Title: Modified adenoviruses Feb. 28, 2023
-
Patent Title: Alphavirus antigen vectors Nov. 29, 2022
-
Patent Title: Alphavirus neoantigen vectors Nov. 22, 2022
-
Patent Title: Alphavirus neoantigen vectors Aug. 23, 2022
-
Patent Title: Neoantigen identification using hotspots Mar. 01, 2022
-
Patent Title: Neoantigen identification, manufacture, and use Nov. 23, 2021
Federal grants, loans, and purchases
Followers on GRTS's company Twitter account
Number of mentions of GRTS in WallStreetBets Daily Discussion
Recent insights relating to GRTS
Recent picks made for GRTS stock on CNBC
ETFs with the largest estimated holdings in GRTS
Flights by private jets registered to GRTS